| HOME >> BIOLOGY >> TECHNOLOGY |
DRUG DEVELOPMENT USING BIOMARKERS: MARKET ENTRY THEORY AND IMPLICATIONS
FIGURE 4 DECISION TREE AND ECONOMICS FOR BIOMARKERS AT POINT OF CARE
Breakeven Analysis of Diagnostic-Enabled Drug Model
FIGURE 5 PRICE, COST, ADOPTION PERCENT FOR BIOMARKER ENVIRONMENT
FIGURE 6 BREAKEVEN LEVEL FOR ADOPTION OF BIOMARKER
Implications for Industry
BIOMARKERS APPLICATIONS: DRUG DEVELOPMENT
Safety/toxicology Biomarkers
TABLE 2 NOVEL SAFETY / TOXICOLOGY BIOMARKERS USED IN CANCER, CARDIO AND RENAL
Dose Selection and Dose Optimization
TABLE 3 NOVEL DOSE SELECTION BIOMARKERS USED IN CANCER, DIABETES, METABOLIC AND LIVER DISEASE
Improved Measurement of Therapeutic Efficacy
Outcome Biomarkers and Surrogate Endpoints
TABLE 4 PATIENT OUTCOME MEASUREMENTS BIOMARKERS
EARLY-STAGE CLINICAL TRIAL APPLICATIONS
LATE-STAGE CLINICAL TRIAL APPLICATIONS
Phase III
Phase IV
BIOMARKERS: CHALLENGES AND OPPORTUNITIES
SUMMARY
CLINICAL VALIDITY: REQUIREMENTS
BIOMARKER OPPORTUNITIES
PRODUCT SUMMARY AND MARKET
GENOMICS
TABLE 5 GLOBAL MARKET FOR BIOMARKERS, THROUGH 2010 ($ MILLIONS)
IMAGING
PROTEOMICS
BIOINFORMATICS
OTHER
Metabolomics
BIOMARKER ADOPTION BY THE PHARMACEUTICAL INDUSTRY
GROWTH DRIVERS AND RESISTORS
FACTORS INFLUENCING BIOMARKER ADOPTION IN CLINICAL TRIALS
CLINICAL TRIAL BENEFITS: COST AND RISK AVOIDANCE
IMPACT OF DRUG FAILURE IN LAST-STAGE CLINICAL TRIALS
Merck: Vicriviroc
Myriad: Flurizan
ADDITIONAL CAPABILITIES BY LARGE SERVICE PLAYERS
TECHNOLOGICAL ADVANCEMENTS IN GENOMICS AND PROTEOMICS
BIOMARKER MARKET FORECAST
TABLE 6 GLOBAL BIOMARKER MARKET FORECAST, THROUGH 2015 ($ MILLIONS)
CHAPTER FOUR: REGULATORY DYNAMICS, INTELLECTUAL PROPERTY, ETHICAL CONSIDERATIONS <
'/>"/>
| SOURCE MDX Copyright©2010 PR Newswire. All rights reserved |